Tumor Necrosis in Pediatric Osteosarcoma: Impact of Modern Therapies

Abstract

Tumor necrosis following preoperative chemotherapy in patients with osteosarcoma is a predictor of overall survival. With modern therapies, 45% of patients are expected to achieve more than 90% tumor necrosis. Investigators at the authors’ center, however, increasingly noted that patients were experiencing inferior necrosis responses. A retrospective study of treated patients at the center was undertaken to examine this. The purpose of this study was to determine (1) whether the number of patients with favorable histological responses had changed over time and (2) whether the percentage of patients with favorable responses was similar to published outcomes. Chart reviews were performed on patients treated from 1993 to 2003 according to the Pediatric Oncology Group 9351, regimen A protocol. Twenty-one patients met all eligibility requirements; 52% of patients had more than 90% necrosis. No correlation existed between degree of necrosis and year of treatment (r = 0.06; P = .8). Patients with osteosarcoma treated at the authors’ institution have comparable tumor necrosis responses to published outcomes, and no change occurred over time. This study stresses the importance of rigorous retrospective reviews before implementing treatment changes.

Keywords

osteosarcoma tumor necrosis prognostic factors chemotherapy survival

Get full access to this article

View all access options for this article.

References

Bacci, G. , Ferrari, S. , Longhi, A. , Forni, C. , Zavatta, M. , Versare, M. , et al. (2002). High-grade osteosarcoma of the extremity: Differences between localized and metastatic tumors at presentation. Journal of Pediatric Hematology Oncology, 24, 27-30.

Barnett, A. G. , van der Pols, J. , & Dobson, A. J. (2005). Regression to the mean: What it is and how to deal with it. International Journal of Epidemiology, 34, 215-220.

Bielack, S. S. , Kempf-Bielack, B. , Delling, G. , Exner, G. U. , Fledge, S. , Helmke, K. , et al. (2002). Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology, 20, 776-790.

Davis, A. M. , Bell, R. S. , & Goodwin, P. J. (1994). Prognostic factors in osteosarcoma: A critical review. Journal of Clinical Oncology, 12, 423-431.

Eilber, F. C. , Rosen, G. , Eckardt, J. , Forscher, C. , Nelson, S. D. , Selch, M. , et al. (2001). Treatment-induced pathologic necrosis: A predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. Journal of Clinical Oncology, 19, 3203-3209.

Goorin, A. M. , Harris, M. B. , Bernstein, M. , Ferguson, W. , Devidas, M. , Siegal, G. P. , et al. (2002). Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A pediatric oncology group trial. Journal of Clinical Oncology, 20(2) 426-433.

Hartford, C. M. , Wodowski, K. S. , Rao, B. N. , Khoury, J. D. , Neel, M. D. , & Daw, N. C. (2006). Osteosarcoma among children aged 5 years or younger: The St. Jude children’s research hospital experience. Journal of Pediatric Hematology Oncology, 28, 43-47.

Jurgens, H. , Winkler, K. , & Gobel, U. (1997). Bone tumours. In C. R. Pinkerton & P. N. Plowman (Eds.), Paediatric oncology (2nd ed., pp. 417-439). London: Chapman & Hall.

Kager, L. , Zoubek, A. , Potschger, U. , Kastner, U. , Flege, S. , Kempf-Bielack, B. , et al. (2003). Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology, 21, 2011-2018.

10.

Link, M. P. , Gebhardt, M. C. , & Meyers, P. A. (2002). Osteosarcoma. In P. A. Pizzo & D. G. Poplack (Eds.), Principles and practice of pediatric oncology (4th ed., pp. 1051-1090). Philadelphia: Lippincott Williams & Wilkins.

11.

Marina, N. , Gebhardt, M. , Teot, L. , & Gorlick, R. (2004). Biology and therapeutic advances for pediatric osteosarcoma. Oncologist, 9, 422-441.

12.

Meyers, P. A. , Schwartz, C. L. , Krailo, M. , Kleinerman, E. , Betcher, D. , Bernstein, M. L. , et al. (2005). Osteosarcoma: A randomized, prospective trial of the addition of the ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. Journal of Clinical Oncology, 23, 2004-2011.

13.

Morton, V. , & Torgerson, D. J. (2003). Effect of regression to the mean on decision making in health care. British Medical Journal, 326, 1083-1084.

14.

Pinkerton, C. R. (1999). Osteogenic sarcoma. In C. R. Pinkerton , A. J. Michalski , & P. A. Veys (Eds.), Clinical challenges in paediatric oncology (pp. 127-134). Oxford, UK: ISIS Medical Medial.

15.

Ragland, B. D. , Bell, W. C. , Lopez, R. R. , & Siegal, G. P. (2002). Cytogenetic and molecular biology of osteosarcoma. Laboratory Investigation, 82, 365-377.

16.

Rosen, G. , Marcove, R. C. , Caparros, B. , Nirenberg, A. , Kosloff, C. , & Huvos, A. G. (1979). Primary osteogenic sarcoma. The rational for pre-operative chemotherapy and delayed surgery. Cancer, 43, 2163-2177.

17.

Zalupski, M. M. , Rankin, C. , Ryan, J. R. , Lucas, D. R. , Muler, J. , Lanier, K. S. , et al. (2004). Adjuvant therapy of osteosarcoma—A phase II trial. Cancer, 100, 818-825.